Format

Send to

Choose Destination
Clin Cancer Res. 2015 Jun 15;21(12):2663-5. doi: 10.1158/1078-0432.CCR-14-3183.

"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.

Author information

1
Stanford University School of Medicine, Stanford, California. gsledge@stanford.edu.
2
Stanford University School of Medicine, Stanford, California.

Abstract

HER2-targeted therapy has moved beyond trastuzumab to include other monoclonals targeting the cell surface, receptor tyrosine kinase inhibitors of HER2, and antibody-drug conjugates. Afatinib, a small molecule receptor tyrosine kinase inhibitor, now joins the ranks of HER2-targeting agents in combination with trastuzumab. The combination brings new opportunities and challenges.

PMID:
26078429
DOI:
10.1158/1078-0432.CCR-14-3183
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center